Carcinoma, Non-Small-Cell Lung
Conditions
Keywords
Carcinoma, Non-Small-Cell Lung
Brief summary
Durvalumab as maintenance in patients who received chemoradiotherapy for unresectable stage III NSCLC: Real World Data from an Expanded Access Program in Brazil
Interventions
None listed
Sponsors
Latin American Cooperative Oncology Group
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients with unresectable stage III NSCLC who completed a platinum-based chemotherapy concurrently or sequentially with radiation therapy without evidence of disease progression 2. Patients who have participated in the Durvalumab EAP in Brazil and have received at least one dose of Durvalumab in the EAP..
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Describe real world data on PFS of patients treated with Durvalumab in stage III NSCLC in the EAP in Brazil | June of 2018 |
Other
| Measure | Time frame |
|---|---|
| - To describe Overall response rate, defined as the proportion of patients who have a partial or complete response to durvalumab therapy. | June of 2018 |
| - To describe Overall survival at 3 years, defined as the time from start of durvalumab therapy to death from any cause. | June of 2018 |
| - To describe the sequence of lines of treatment in patients which have disease progression after durvalumab. | June of 2018 |
Countries
Brazil
Outcome results
None listed